Although neither the company nor the indication can be named, Nanexa is able to state that the condition being investigated is chronic. The goal is to use PharmaShell to transform the company’s current drug, into one that is dosed less frequently.

“This is further affirmation that major pharmaceutical companies appreciate the value of PharmaShell and what Nanexa is doing to transform quick-release, regularly dosed drugs into long-acting, more manageable therapeutics,” says David Westberg, CEO, Nanexa. “Patients globally are often responsible for self-administering regular doses or visiting clinics for injections given by healthcare professionals. This approach frequently result in poor treatment adherence, leading to suboptimal patient outcomes and increased overall costs.”